Research programme: NR2B NMDA receptor negative allosteric modulators - BioCrea

Drug Profile

Research programme: NR2B NMDA receptor negative allosteric modulators - BioCrea

Alternative Names: NR2B NAMs - BioCrea

Latest Information Update: 02 May 2014

Price : $50

At a glance

  • Originator biocrea GmbH
  • Class Small molecules
  • Mechanism of Action NR2B N-Methyl D-Aspartate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Depressive disorders; Major depressive disorder

Most Recent Events

  • 23 Apr 2014 BioCrea is actively seeking to out-license or partner its NR2B NMDA receptor negative allosteric modulators programme as of 23 Apr 2014. http://www.biocrea.com
  • 30 Jan 2014 Early research in Depressive disorders (treatment-resistant) in Germany (unspecified route)
  • 30 Jan 2014 Early research in Major depressive disorder in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top